JP2008543877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543877A5 JP2008543877A5 JP2008517206A JP2008517206A JP2008543877A5 JP 2008543877 A5 JP2008543877 A5 JP 2008543877A5 JP 2008517206 A JP2008517206 A JP 2008517206A JP 2008517206 A JP2008517206 A JP 2008517206A JP 2008543877 A5 JP2008543877 A5 JP 2008543877A5
- Authority
- JP
- Japan
- Prior art keywords
- bak
- apoptosis
- beta
- corneal epithelial
- corneal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000686 benzalkonium chloride Drugs 0.000 description 11
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
- 102100035000 Thymosin beta-4 Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010822 cell death assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 108010079996 thymosin beta(4) Proteins 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69126105P | 2005-06-17 | 2005-06-17 | |
| US77694706P | 2006-02-28 | 2006-02-28 | |
| PCT/US2006/023758 WO2006138707A1 (en) | 2005-06-17 | 2006-06-19 | Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543877A JP2008543877A (ja) | 2008-12-04 |
| JP2008543877A5 true JP2008543877A5 (enExample) | 2009-07-23 |
Family
ID=37570786
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517206A Pending JP2008543877A (ja) | 2005-06-17 | 2006-06-19 | Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法 |
| JP2008517207A Pending JP2008543878A (ja) | 2005-06-17 | 2006-06-19 | 凍結乾燥したかまたは凍結乾燥させることができる形態であるｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物 |
| JP2008517208A Withdrawn JP2008543879A (ja) | 2005-06-17 | 2006-06-19 | Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物ならびに方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517207A Pending JP2008543878A (ja) | 2005-06-17 | 2006-06-19 | 凍結乾燥したかまたは凍結乾燥させることができる形態であるｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物 |
| JP2008517208A Withdrawn JP2008543879A (ja) | 2005-06-17 | 2006-06-19 | Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物ならびに方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US20090131313A1 (enExample) |
| EP (4) | EP1896050A4 (enExample) |
| JP (3) | JP2008543877A (enExample) |
| KR (3) | KR20080033939A (enExample) |
| CN (1) | CN105106931A (enExample) |
| AU (3) | AU2006261155A1 (enExample) |
| CA (3) | CA2612410A1 (enExample) |
| HK (1) | HK1218248A1 (enExample) |
| IL (4) | IL187522A0 (enExample) |
| MX (3) | MX2007015958A (enExample) |
| WO (3) | WO2006138707A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010010177A (es) * | 2008-03-17 | 2012-08-23 | Regenerx Biopharmaceuticals | Fragmentos de beta timosina mejorada. |
| CN101297965B (zh) * | 2008-06-16 | 2011-01-05 | 浙江省中医药研究院 | 胸腺肽β4在制备防治支气管哮喘药物中的应用 |
| EP2485765A2 (en) * | 2009-10-09 | 2012-08-15 | Board Of Regents The University Of Texas System | Photokinetic ocular drug delivery methods and apparatus |
| WO2012126047A1 (en) * | 2011-03-18 | 2012-09-27 | Adistem Ltd | Agent and method for treating pain and reducing inflammation |
| CN104271142B (zh) | 2012-03-01 | 2017-07-04 | 福斯特斯特林研究公司 | 含有α连接蛋白C‑末端(ACT)肽的局部凝胶 |
| EP2698162A1 (en) * | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
| PL3065756T3 (pl) | 2013-11-07 | 2019-07-31 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Stabilnie przechowywane liofilizowane formulacje tripeptydowe |
| US10302658B2 (en) | 2014-03-12 | 2019-05-28 | University Of Virginia Patent Foundation | Compositions and methods for treating eye infections and disease |
| JP6634451B2 (ja) | 2014-10-22 | 2020-01-22 | ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． | チモシンβ４を含有する組成物、およびそれを含む医薬製剤 |
| MA41299A (fr) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
| KR20170021667A (ko) | 2015-08-18 | 2017-02-28 | 주식회사 지트리비앤티 | 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물 |
| US9867868B2 (en) * | 2015-08-18 | 2018-01-16 | G-Treebnt Co., Ltd. | Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid |
| US10744088B2 (en) | 2015-10-06 | 2020-08-18 | G-Treebnt Co., Ltd. | Method for preparing ophthalmic preparation containing thymosin beta-4 |
| KR102488796B1 (ko) * | 2016-07-18 | 2023-01-13 | 리젠트리 엘엘씨 | 안구 건조증 치료 방법 |
| KR102115158B1 (ko) | 2016-11-29 | 2020-05-26 | 주식회사 지트리파마슈티컬 | 티모신 베타 4 를 함유하는 제형 |
| US20190381136A1 (en) * | 2017-02-21 | 2019-12-19 | Tearsolutions, Inc. | Stable peptide compositions |
| KR102340750B1 (ko) * | 2017-03-03 | 2021-12-21 | 에이치엘비테라퓨틱스 주식회사 | 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제 |
| KR101910908B1 (ko) * | 2017-06-14 | 2018-10-24 | (주)휴온스 | Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물 |
| US10342824B2 (en) | 2017-07-17 | 2019-07-09 | Dr. Marlowe's Weight Loss Institute, P.L.L.C. | Supplement for treating side effects of medications which cause metabolic acidosis |
| AU2018372396A1 (en) * | 2017-11-24 | 2020-06-25 | HLB Therapeutics Co., Ltd. | Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient |
| JP2023546757A (ja) | 2020-10-22 | 2023-11-07 | シークエル・バイオ・インコーポレイテッド | ペプチド製剤および眼科におけるその使用 |
| WO2024006653A2 (en) * | 2022-07-01 | 2024-01-04 | Tearsolutions, Inc. | Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444757A (en) * | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
| US4906613A (en) | 1985-11-05 | 1990-03-06 | Schering Corporation | Antiglaucoma compositions and methods |
| NZ235556A (en) * | 1986-11-05 | 1991-06-25 | Ethicon Inc | Breast milk substitute containing recombinant human egf |
| FR2647675B1 (fr) | 1989-06-05 | 1994-05-20 | Sanofi | Utilisation d'un derive de la statine dans le traitement des affections oculaires |
| US5564345A (en) | 1993-05-11 | 1996-10-15 | Park Ohio Industries Inc. | Stackable table, table assembly, and tray and table combination |
| CA2132826C (en) * | 1992-05-06 | 1999-01-05 | Masood Chowhan | Use of borate-polyol complexes in ophthalmic compositions |
| US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
| US5593964A (en) | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
| AU3070395A (en) * | 1994-07-22 | 1996-02-22 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
| GB9806632D0 (en) | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
| WO2000006190A1 (en) * | 1998-07-30 | 2000-02-10 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | THYMOSIN β4 PROMOTES WOUND REPAIR |
| US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
| AU2001292881A1 (en) * | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| JP2005506293A (ja) * | 2001-03-15 | 2005-03-03 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法 |
| EP1427432A4 (en) * | 2001-08-29 | 2008-01-23 | Regenerx Biopharmaceuticals | METHOD FOR HEALING OR PREVENTING IGNITION, DAMAGE, AND OTHER CHANGES ARISING BEFORE, DURING, OR DIRECTLY TO A MYOKARDIN FARM, WITH THYMOSINE BETA 4, ANALOGUE, ISOFORMS AND OTHER DERIVATIVES |
| WO2003073911A2 (en) * | 2002-02-28 | 2003-09-12 | Georgetown University | Method and composition for detection and treatment of breast cancer |
| PL374700A1 (pl) * | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka |
| EP1613369A4 (en) * | 2003-03-31 | 2008-10-01 | Regenerx Biopharmaceuticals | COMPOSITIONS AND METHODS OF DELIVERING THYMOSINE BETA 4, ANALOGUE, ISOFORMS AND OTHER DERIVATIVES |
| WO2004099768A1 (en) * | 2003-05-05 | 2004-11-18 | Regenerx Biopharmaceuticals, Inc. | Method for detecting development of a physiological disorder in a subject |
| WO2017017553A1 (en) | 2015-07-30 | 2017-02-02 | Semiconductor Energy Laboratory Co., Ltd. | Manufacturing method of light-emitting device, light-emitting device, module, and electronic device |
-
2006
- 2006-06-19 MX MX2007015958A patent/MX2007015958A/es not_active Application Discontinuation
- 2006-06-19 WO PCT/US2006/023758 patent/WO2006138707A1/en not_active Ceased
- 2006-06-19 KR KR1020087000982A patent/KR20080033939A/ko not_active Ceased
- 2006-06-19 AU AU2006261155A patent/AU2006261155A1/en not_active Abandoned
- 2006-06-19 CA CA002612410A patent/CA2612410A1/en not_active Abandoned
- 2006-06-19 MX MX2007015957A patent/MX2007015957A/es active IP Right Grant
- 2006-06-19 KR KR1020087000983A patent/KR20080021782A/ko not_active Withdrawn
- 2006-06-19 CA CA002612522A patent/CA2612522A1/en not_active Abandoned
- 2006-06-19 JP JP2008517206A patent/JP2008543877A/ja active Pending
- 2006-06-19 CN CN201510532998.4A patent/CN105106931A/zh active Pending
- 2006-06-19 US US11/917,869 patent/US20090131313A1/en not_active Abandoned
- 2006-06-19 AU AU2006261156A patent/AU2006261156B2/en not_active Ceased
- 2006-06-19 EP EP06785093A patent/EP1896050A4/en not_active Withdrawn
- 2006-06-19 US US11/917,883 patent/US20080214456A1/en not_active Abandoned
- 2006-06-19 US US11/917,848 patent/US8383576B2/en not_active Expired - Fee Related
- 2006-06-19 EP EP06785091A patent/EP1904080A4/en not_active Withdrawn
- 2006-06-19 EP EP17204441.4A patent/EP3326647A1/en not_active Ceased
- 2006-06-19 MX MX2007015956A patent/MX2007015956A/es not_active Application Discontinuation
- 2006-06-19 WO PCT/US2006/023759 patent/WO2006138708A1/en not_active Ceased
- 2006-06-19 JP JP2008517207A patent/JP2008543878A/ja active Pending
- 2006-06-19 EP EP06785092A patent/EP1906986A4/en not_active Ceased
- 2006-06-19 CA CA002612405A patent/CA2612405A1/en not_active Abandoned
- 2006-06-19 KR KR1020087000980A patent/KR20080018268A/ko not_active Withdrawn
- 2006-06-19 JP JP2008517208A patent/JP2008543879A/ja not_active Withdrawn
- 2006-06-19 WO PCT/US2006/023760 patent/WO2006138709A2/en not_active Ceased
- 2006-06-19 AU AU2006261157A patent/AU2006261157A1/en not_active Abandoned
-
2007
- 2007-11-20 IL IL187522A patent/IL187522A0/en unknown
- 2007-11-25 IL IL187617A patent/IL187617A0/en unknown
- 2007-11-29 IL IL187781A patent/IL187781A/en active IP Right Grant
-
2011
- 2011-08-26 US US13/219,394 patent/US9821030B2/en active Active
-
2012
- 2012-03-06 IL IL218504A patent/IL218504A/en active IP Right Grant
-
2016
- 2016-01-19 US US15/000,297 patent/US9585941B2/en active Active
- 2016-06-01 HK HK16106215.8A patent/HK1218248A1/zh unknown
- 2016-06-15 US US15/183,334 patent/US20160287673A1/en not_active Abandoned
-
2017
- 2017-01-24 US US15/414,014 patent/US20170128540A1/en not_active Abandoned
- 2017-10-12 US US15/782,293 patent/US10004785B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543877A5 (enExample) | ||
| Pinheiro et al. | The impact of glaucoma medications on corneal wound healing | |
| EP2440194B1 (en) | Methods and compositions for the induction of hypothermia | |
| PT1811959E (pt) | Composições oftálmicas e métodos para tratamento dos olhos | |
| RU2015143521A (ru) | Лекарственные формы химерных цитокинов для глазной доставки | |
| Shioda et al. | Osmosensitive taurine transporter expression and activity in human corneal epithelial cells | |
| Choy et al. | Antioxidant content and ultraviolet absorption characteristics of human tears | |
| CN116637066A (zh) | 亚铁离子在制备治疗细菌感染产品中的应用 | |
| Olivieri et al. | Experimental evidence of the healing properties of lactobionic acid for ocular surface disease | |
| ES2475790T3 (es) | Composición oft�lmica basada en ácido lactobi�nico útil para reducir el edema de córnea e inflamación | |
| Alemi et al. | The neuropeptide α-Melanocyte–stimulating hormone prevents persistent corneal edema following injury | |
| Kolar et al. | Role of host-defence peptides in eye diseases | |
| RU2139094C1 (ru) | Композиция для обработки контактных линз | |
| US20210046018A1 (en) | Resveratrol medication for the treatment of ocular pain and method of use thereof | |
| US20200230115A1 (en) | Methods of treating influenza-associated viral pneumonia | |
| JP6159241B2 (ja) | 筋萎縮抑制剤 | |
| BARR et al. | Cryoglobulinemia: a case report | |
| Goralska et al. | Vitreous humor changes expression of iron-handling proteins in lens epithelial cells | |
| CN116785413A (zh) | Trpm7的激酶结构域m7ck在制备ad治疗药物中的应用 | |
| Qiu et al. | Effect of ozone oxidative preconditioning on oxidative stress injury in a rat model of kidney transplantation | |
| JP5650864B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| Giannaccare et al. | A novel osmoprotectant tear substitute for the treatment of dry eye disease | |
| Bailey et al. | Evaluation of the effects of tricaine methanesulfonate on retinal structure and function in koi carp (Cyprinus carpio) | |
| EP1067907B1 (en) | Ocular irrigating solution | |
| Dave et al. | Comparative in-vitro transcorneal permeation studies of aqueous drop of Esmolol HCl through excised goat, sheep, and buffalo corneas |